Telaprevir Experience From Turkey
Makaleler > Tam Makale · 2015
Yazarlar: Suheyla Komur, Behice Kurtaran, Ayse Seza Inal, Hüsnü PULLUKÇU, Aslihan Ulu, Ferit Kuscu, Tansu YAMAZHAN, Yesim Tasova, Hasan Salih Zeki Aksu
Hepatitis Monthly, Uluslararası, Wos, 2015, cilt 15, ss e25639-e25639
Özet
BACKGROUND: In patients with chronic hepatitis C, triple drug regimens containing a protease inhibitor, peginterferon and ribavirin were found to significantly increase sustained virologic response rates compared to dual drug regimen containing pegylated interferon and ribavirin, especially in genotype 1. OBJECTIVES: In Turkey, telaprevir has been used since March 2013. We aimed to evaluate results of patients with chronic hepatitis C treated with telaprevir, peginterferon and ribavirin. PATIENTS AND METHODS: We evaluated 28 patients with genotype 1 chronic hepatitis C infection treated with triple drug regimen containing telaprevir, in three medical centers in Turkey, retrospectively. Demographic data of patients, treatment indications, adverse events and outcomes were recorded. RESULTS: Of 28 patients intended to treat, 25 (89.2%) patients completed the treatment. Overall, 21 (82.1%) patients had relapse and five patients were non-responder. Regarding the treatment outcomes of Telaprevir based regimen, 20/26 patients achieved sustained virological response. Pruritus, rash, dysgeusia, anorectal discomfort and anemia were main adverse effects. Blood transfusion and ribavirin dose reduction required for 7 and 11 patients, respectively. Due to several adverse effects, 10 patients were hospitalized. CONCLUSIONS: Although more frequent and severe adverse effects, telaprevir has been promising for patients with treatment-experienced hepatitis C.